Lung Cancer SPORE

Cores

CLINICAL CORE

Core Co-leaders: Joel Weissfeld, PhD; James D. Luketich, MD; Ethan Argiris, MD

A number of other clinical trials are currently ongoing at UPCI and most are expected to be completed in 2008. These studies include the following:

  1. Phase II Trial of RAD001 (Everolimus) in Previously Treated Small Cell Lung Cancer (Investigator-initiated. PI: Argiris. UPCI #06-049)
  2. A Phase II Study of Cetuximab in Combination with External Beam Radiation Followed by Consolidation Chemotherapy for Patients with Locally Advanced Non-Small Cell Lung Cancer (NSCLC) (Investigator-initiated. PI: Argiris. UPCI #05-106)
  3. Phase II Study of Bortezomib (PS-341) for Patients with Advanced Bronchiolo-Alveolar Carcinoma (BAC) or Adenocarcinoma with BAC Features (NCI 7003, CCC-P PhII-57) (UPCI PI: Argiris. UPCI #04-163)
  4. Phase II Study of C225 (Cetuximab) for the Treatment of Patients with Advanced Bronchioalveolar Carcinoma (BAC) or Adenocarcinoma with BAC Features (ECOG PI: Ramalingam. ECOG 1504) (UPCI PI Argiris. UPCI #05-093)